Screening for trisomies by cfDNA testing of maternal blood in twin pregnancy: update of the Fetal Medicine Foundation results and meta-analysis. by Gil Mira, María del Mar et al.
 
Screening for trisomies by cfDNA testing of maternal blood in twin pregnancy: update of the Fetal 
Medicine Foundation results and meta-analysis. 
 
María del Mar Gil,1,2 Slavyana Galeva,1,3 Jacques Jani,4 Liountmila Konstantinidou,1 Ranjit Akolekar,3,5 
María Nieves Plana,6 Kypros H. Nicolaides.1 
 
1. Harris Birthright Research Centre of Fetal Medicine, King’s College Hospital, London, UK. 
2. Universidad Francisco de Vitoria, UFV, Pozuelo de Alarcón, Madrid, Spain. 
3. Department of Fetal Medicine, Medway Maritime Hospital, Kent. 
4. Department of Obstetrics and Gynecology, University Hospital Brugmann, Brussels, Belgium. 
5. Institute of Medical Sciences, Canterbury Christ Church University, Chatham, UK. 
6. Department of Preventive Medicine and Public Health, Hospital Príncipe de Asturias, Alcalá de 




Short title: cfDNA testing in twin pregnancies 
 
Acknowledgement: The study was supported by a grant from The Fetal Medicine Foundation (UK 
Charity No: 1037116). The cost of collection and analysis of some of the samples for the cell-free DNA 
test was covered by Roche/Ariosa Diagnostics, Inc. San Jose, CA, USA. These organizations had no 




Professor K Nicolaides 
Fetal Medicine Research Institute, 
King's College Hospital, 
16-20 Windsor Walk, 





Objective: To report on the routine clinical implementation of cell-free (cf)DNA analysis of maternal 
blood for trisomies 21, 18 and 13 in twin pregnancies and to define the performance of the test by 
combining our results with those arising from systematic review of the literature. 
 
Methods: The data for the study were derived from prospective screening for trisomies 21, 18 and 13 
in twin pregnancies at 10+0-14+1 weeks’ gestation. Two populations were included; first self-referred 
women  to the Fetal Medicine Centre in London or Brugmann University Hospital in Brussels and 
second, women selected for the cfDNA test after routine first-trimester combined testing in one of two 
National Health Service hospitals in England. This dataset was used to determine the performance of 
screening for the three trisomies. Search of Medline, Embase, CENTRAL (The Cochrane Library), 
ClinicalTrials.gov and ICTRP (World Health Organization) was carried out to identify all peer-reviewed 
publications on clinical validation or implementation of maternal cfDNA testing for trisomies 21, 18 and 
13 in twin pregnancies. Meta-analysis was then performed using our data and data from the studies 
identified by the literature search. 
  
Results: In our dataset of 997 twin pregnancies with a cfDNA result and known outcome, the test 
classified correctly 16 (94.1%) of the 17 cases of trisomy 21, 9 (90.0%) of 10 of trisomy 18, 1 (50.0%) 
of 2 of trisomy 13 and 963 (99.5%) of 968 cases without any of the three trisomies. The literature 
search identified 7 relevant studies, excluding our papers because their data are included in the 
current study. In the combined total of our study and the 7 studies identified by the literature search 
there were 56 trisomy 21 and 3,718 non-trisomy 21 twin pregnancies; the pooled weighted detection 
rate (DR) and false positive rate (FPR) were 98.2% (95% CI 83.2, 99.8%) and 0.05% (95% CI 0.01, 
0.26%), respectively. In the combined total of 18 cases of trisomy 18 and 3,143 non-trisomy 18 
pregnancies the pooled weighted DR and FPR were 88.9% (95% CI 64.8, 97.2%) and 0.03% (95% CI 
0.00, 0.33%), respectively. For trisomy 13, there were only 3 affected cases and 2 (66.7%) of these 
were detected by the cfDNA test at FPR of 0.19% (5/2,569). 
 
Conclusions: Performance of cfDNA testing for trisomies 21 in twin pregnancies is similar to that 
reported for singleton pregnancies. The number of cases of trisomies 18 and 13 is too small for 
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INTRODUCTION  
 
In singleton pregnancies, cell-free (cf) DNA analysis of maternal blood provides effective screening for 
trisomies 21, 18 and 13. A recent meta-analysis of clinical validation studies reported that in the 
combined total of 1963 cases of trisomy 21 and 223 932 non-trisomy 21 singleton pregnancies, the 
weighted pooled detection rate (DR) was 99.7% (95% CI, 99.1-99.9%) and false positive rate (FPR) 
was 0.04% (95% CI, 0.02-0.07%); in a total of 560 cases of trisomy 18 and 212,019 unaffected 
pregnancies the pooled weighted DR and FPR were 98.2% (95% CI 95.5-99.2%) and 0.05% (95% CI 
0.03-0.07%) and in a total of 119 cases of trisomy 13 and 212,883 unaffected singleton pregnancies 
the pooled weighted DR and FPR were 99.0% (95% CI 65.8-100%) and 0.04% (95% CI 0.02-0.07%).1 
In contrast to singleton pregnancies, data of cfDNA testing in twins is very limited; the meta-analysis 
reported that only five studies had examined twin pregnancies prospectively and in a total of 24 cases 
of trisomy 21 and 1111 non-trisomy 21 cases the DR was 100% and FPR was 0%.1  
 
In previous studies we reported our data on cfDNA testing for trisomies in twins. In the first study, 
which included stored and prospectively collected samples, the cfDNA test correctly classified 11 of 12 
cases of trisomy 21, 1 of 1 of trisomy 18, 1 of 1 of trisomy 13 and all 241 non-trisomic pregnancies.2 In 
the second study, we reported the results of prospective screening in twin pregnancies; the cfDNA test 
correctly classified 11 of 12 cases of trisomy 21, 5 of 5 cases of trisomy 18 and all the 334 non-
trisomic pregnancies.3 In the third study, we reported performance of cfDNA testing in 417 
prospectively examined pregnancies; the cfDNA test correctly identified 8 of 8 cases of trisomy 21, 3 
of 4 cases of trisomy 18, 0 of the 1 case of trisomy 13 and 403 (99.8%) of the 404 non-trisomic 
pregnancies.4 In the fourth study, we performed cfDNA testing in pregnancies identified by the 
combined test as being at intermediate or high risk for trisomies; the cfDNA test correctly identified 6 
of 6 cases of trisomy 21, 2 of 3 cases of trisomy 18 and all 206 non-trisomic pregnancies.5 
 
The objectives of this study are first, to report our updated experience on prospective first-trimester 
screening for trisomies in twins by cfDNA testing and second, to carry out a meta-analysis of all 





Update of the Fetal Medicine Foundation results 
 
Study design and participants  
 
The data for the study were derived from prospective screening for trisomies 21, 18 and 13 in twin 
pregnancies at 10+0-14+1 weeks’ gestation. Two populations were included; first self-referred women  
to the Fetal Medicine Centre in London, which is a private clinic6, or Brugmann University Hospital, 
which is public hospital in Brussels and second, women selected for the cfDNA test after routine first-
trimester combined testing in one of two National Health Service hospitals in England.5,7 The patients 
were examined between October 2012 and January 2018. The study was approved by the 
appropriate Ethics Committees (NREC reference 13/LO/0885, NREC reference 19/HRA/0576, CE 
2014/5).  
 
We recorded maternal characteristics and medical history, including maternal age, racial origin (White, 
Black, South Asian, East Asian and mixed), method of conception (natural or assisted conception 
requiring the use of ovulation drugs or in-vitro fertilization), cigarette smoking during pregnancy (yes or 
no) and parity (parous or nulliparous if no previous pregnancy at or after 24 weeks’ gestation). An 
ultrasound scan was carried out to determine gestational age from the measurement of the crown-
rump length8 of the larger fetus and chorionicity by examining the junction of the intertwin membrane 
with the placenta.9  
 
Women provided written informed consent and maternal blood (20 mL) was collected into either Cell-
Free DNA BCT tubes (Streck, Omaha, NE) or Roche Cell-Free DNA Collection Tubes (Roche, 
Pleasanton, CA). These were shipped via courier to Roche/Ariosa Diagnostics, Inc. (San Jose, CA, 
USA) where they were processed within 7 days of collection. Targeted cfDNA testing for fetal trisomy 
was performed using the Harmony® prenatal test as described previously.10-13 Harmony® uses 
DANSR assays targeting sequences on chromosomes 13, 18, and 21 for chromosome quantitation 
and single nucleotide polymorphisms on chromosomes 1 to 12 for fetal fraction measurement. 
Products of the DANSR assays can be quantified using either next-generation sequencing or a 
custom microarray; both were used during the course of this study. The data are analysed with the 
fetal fraction optimized FORTE algorithm, which calculates probability scores for fetal trisomy, with 
greater than 1% considered to be high probability. In cases where the cfDNA test did not provide 
results the parents were offered repeat testing or to rely on the results of the combined test in deciding 
whether to have an invasive test or not. In cases with a high-risk result from the cfDNA test, the 
parents were advised to consider having invasive fetal karyotyping before deciding on the further 
management of their pregnancy.  
 
Patient characteristics, results of the investigations and pregnancy outcome were recorded in a 
database. The outcomes were divided into first, trisomy 21, 18 or 13 if the karyotype of chorionic villi, 
amniotic fluid or neonatal blood demonstrated the relevant trisomy in one or both babies, second, no 
trisomy 21, 18 or 13 if the karyotype was normal or both neonates were phenotypically normal, third, 
no known karyotype in both fetuses because the pregnancies resulted in termination or embryo 
reduction, miscarriage or stillbirth and no karyotyping of fetal tissue was carried out, and fourth, 




Descriptive data were presented in median and interquartile range (IQR) for continuous variables and 
in numbers and percentages for categorical variables.  
 
Systematic review and meta-analysis 
 
Literature search and study selection 
 
Searches of Medline via PubMed, Embase and CENTRAL (The Cochrane Library) were performed to 
identify clinical validation or implementation studies of maternal cfDNA testing in screening for 
aneuploidies in twin pregnancies; additionally, ClinicalTrials.gov and WHO International Clinical Trials 
Registry Platform (ICTRP) were also searched for ongoing or recently completed trials. The study 
period was from January 2011, when the first such study was published, to 9th March 2019; the initial 
search was 8th December 2018 and this was updated with autoalerts in Medline. A list of relevant 
citations was generated from these databases using the search strategies included in Appendix 1. 
This review was registered in PROSPERO international database for systematic reviews (reference: 
CRD42019121506). 
 
The abstracts of citations were examined by two reviewers (M.M.G., S.G) to identify all potentially 
relevant articles, which were then examined in full-text form. Reference lists of relevant original and 
review articles were hand-searched for additional reports. Agreement about potential relevance was 
reached by consensus and by consultation with a third reviewer (K.H.N.).  
 
The inclusion criteria were peer-reviewed studies reporting on clinical validation or implementation of 
maternal cfDNA testing in screening for aneuploidies in twin pregnancies, in which data on pregnancy 
outcome were provided for more than 85% of the study population. Proof-of-principle articles and 
studies in which the laboratory scientists carrying out the tests were aware of fetal karyotype or 
pregnancy outcome were excluded. We also excluded case-control studies because they tend to 
introduce an optimistic bias to the estimates of diagnostic performance.  
 
Data extraction and meta-analysis of data from all studies 
 
Data regarding sample size, gestational age at analysis, method used for cfDNA testing and DR or 
sensitivity and FPR or specificity for non-mosaic trisomies 21,18 and 13 were obtained from each 
study included in the systematic review and documented in contingency tables. In the construction of 
these tables, we used the results from the cfDNA test and excluded those cases in which the test 
failed to give a result. In the calculation of FPR, we included all euploid and aneuploid cases other 
than the aneuploidy under investigation. Authors were contacted when clarifications were required in 
the interpretation of the data. 
 
We extracted data from the primary studies to obtain the four cell values of a diagnostic 2×2 table to 
calculate test accuracy measures of DR and FPR. The analyses were stratified according to the 
different conditions (trisomy 21 and trisomy 18). We calculated DR and FPR with corresponding 95% 
CIs for individual studies and displayed them in forest plots to investigate heterogeneity. We pooled 
the DR and FPR estimates using bivariate random-effects regression models. The bivariate model 
assumes that logit transformations of DR and FPR are negatively correlated and follow a bivariate 
normal distribution14. We computed the positive and negative likelihood ratios from the pooled 
estimates of DR and FPR. Heterogeneity among studies was quantified with the variance of the logit 
of accuracy indices as estimated by the bivariate model. 
 
Publication bias was not analyzed given the limited power of available tests and the uncertainty about 
interpreting statistical evidence of funnel plot asymmetry as necessarily implying publication bias.15 
For trisomy 13 there was an insufficient number of cases for meaningful meta-analysis and we 
therefore computed average DR and FPR values.  
 









A total of 1122 twin pregnancies had cfDNA testing, but 125 (11.1%) of these were excluded from 
further analysis either because the cfDNA test did not provide a result (n=52), the pregnancies ended 
in termination, miscarriage or stillbirth with no known karyotype (n=45) or there was loss to follow up 
(n=28). 
 
In the 997 cases included in the study, 854 (85.7%) were dichorionic and 143 (14.3%) were 
monochorionic; the median maternal age was 38.0 (IQR 34.5-41.0) years, the median maternal weight 
was 69.0 (IQR 60.4-82.6) kg and the median gestational age at sampling was 12.1 (IQR 10.7-12.9) 
weeks. The racial origin of the women was White in 772 (77.4%), South Asian in 65 (6.5%), East 
Asian in 32 (3.2%), Black in 104 (10.4%) and mixed in 24 (2.4%). Conception was natural in 766 
(76.8%) and after use of assisted reproductive techniques in 231 (23.2%). 
 
The study population of 997 pregnancies included 17 with trisomy 21, 10 with trisomy 18, 2 with 
trisomy 13 and 968 without trisomy 21, 18 or 13; one case of trisomy 18 was in a monochorionic twin 
pregnancy where the two fetuses were affected and all the other trisomic cases were in the 
dichorionic pregnancies where only one fetus was trisomic and the cotwin was non-trisomic. 
 
Performance of screening 
 
The cfDNA test classified correctly 16 (94.1%) of the 17 cases of trisomy 21, 9 (90.0%) of 10 of 
trisomy 18, 1 (50.0%) of 2 of trisomy 13 and 963 (99.5%) of 968 cases without any of the three 
trisomies. One case each of trisomy 21, trisomy 18 and trisomy 13 was classified as normal. In the 
non-trisomic group, 4 cases were classified as trisomy 13 and 1 as trisomy 21 and therefore, the 
combined FPR was 0.52% (5/968).  
 




The search identified 329 potentially relevant citations, but 322 were excluded because they were 
non-relevant publications, conference abstracts rather than peer-reviewed papers, review articles or 
opinions, studies not on twins, case-control studies, or studies on clinical implementation of cfDNA 
testing in screening for aneuploidies in which pregnancy outcome data were provided for fewer than 
85% of the study population, proof-of-principle studies reporting laboratory techniques rather than 
clinical validation of a predefined method of maternal blood cfDNA analysis (Figure 1). In total, 9 
relevant studies were identified4,5,17-23 but two of these4,5 were excluded from the meta-analysis 
because their data are included in the updated Fetal Medicine Foundation results presented above. 
The characteristics of our current study and the seven ones identified by the literature search are 
summarized in Table 1.  
 
Methodological quality of the selected studies 
 
The methodological quality of the selected studies, assessed by the Quality Assessment tool for 
Diagnostic Accuracy Studies (QUADAS-2)24 is illustrated in Figure 2. This tool comprises four 
domains; each one is assessed in terms of risk of bias and the first three are also assessed in terms 
of concerns regarding applicability.  
 
Risk of bias 
 
The first domain relates to patient selection. A study was considered to be at low risk of bias if the 
cfDNA test was carried out in a consecutive or random sample of patients; all the studies were 
classified as being at high risk of bias because either the samples were not explicitly stated to have 
been consecutive or selected at random. The second domain relates to the index test; all included 
studies were considered to be at low risk of bias because the cfDNA test was carried out and the 
results given by the laboratory without prior knowledge of the fetal karyotype or pregnancy outcome. 
The third domain relates to the reference standard; all included studies were considered to be at low 
risk of bias because the method of diagnosing the chromosomal abnormality under investigation 
including karyotyping or neonatal examination was accepted to be true. The fourth domain relates to 
flow and timing. A study was considered to be at low risk of bias if first, in the calculation of 
performance of screening, all patients in the study population had a result from both the cfDNA test 
and pregnancy outcome and, second, if the method of classifying the outcome result (invasive testing 
or clinical examination) was the same in all cases in the study population. All but one study18 were 
classified as being at high risk of bias because cfDNA testing was not carried out or did not provide 
results in all cases and/or there was no complete follow-up and/or the method of determining outcome 
was not the same in all cases. 
 
Concerns regarding applicability 
 
In the context of screening for fetal aneuploidies by cfDNA analysis of maternal blood in the general 
population, the first domain relates to patient selection and all the studies were classified as being at 
high risk of concerns regarding applicability because in these studies the test was not carried out in 
the general population but in a mixture of low- and high-risk pregnancies, where some of the patients 
had had another screening test before opting for cfDNA testing. In terms of the second and third 
domains on index test and reference standard, respectively, all studies were classified as being at low 
risk of bias and were also considered as being at low risk of concerns regarding applicability. 
 
Method of analyzing samples 
 
The studies included in the meta-analysis used one of two methods for analysis of cfDNA in maternal 
blood: massively parallel sequencing or targeted analysis (either by next-generation sequencing or by 
a custom microarray) (Table 1).  
 
Nature of the studies 
 
All studies included in this meta-analysis were prospective; three studies were in high-risk 
pregnancies and five examined a mixture of high-risk and routine populations (Table 1). The 
proportion of monochorionic twin pregnancies ranged from 3.2% to 42.4%.  
 
Meta-analysis and performance of screening for aneuploidies 
 
The DR and FPR for each study, weighted pooled data and heterogeneity between studies (variance 
of the logit sensitivity and specificity) are provided in Tables 2 and 3; sensitivity and specificity are 




A total of 8 studies reported on the performance of screening by cfDNA analysis for trisomy 21 in a 
combined total of 56 cases of trisomy 21 and 3718 non-trisomy 21 twin pregnancies (Table 2, Figure 
3). Among individual studies, the DR varied between 94.1% and 100% and the FPR varied between 
0% and 0.24%. The weighted pooled DR and FPR were 98.2% (95% CI 83.2, 99.8%) and 0.05% 




A total of 5 studies reported on the performance of screening by cfDNA analysis for trisomy 18 in a 
combined total of 18 cases of trisomy 18 and 3,143 non-trisomy 18 twin pregnancies (Table 3, Figure 
4). Among individual studies, the DR varied between 50.0% and 100% and the FPR varied between 
0% and 0.10%. The weighted pooled DR and FPR were 88.9% (95% CI 64.8, 97.2%) and 0.03% 




A total of three studies reported on the performance of screening by cfDNA analysis for trisomy 13 in 
a combined total of three cases of trisomy 13 and 2,549 non-trisomy 13 twin pregnancies. In our study 
1 of 2 affected cases were detected by cfDNA testing at FPR of 0.4% (4/995). In the second study23 
the one affected case was detected at FPR of 0% (0/1156). In the third study21 there were no cases of 






Principal findings of the study  
 
The results of our study and the meta-analysis of cfDNA testing in maternal blood in twin pregnancies 
suggest that the performance of the test for trisomy 21 may be similar to that in singleton pregnancies. 
In the combined total of 56 trisomy 21 and 3,718 non-trisomy 21 twin pregnancies the pooled 
weighted DR and FPR were 98.2% (95% CI 83.2, 99.8%) and 0.05% (95% CI 0.01, 0.26%), 
respectively; in our meta-analysis of studies in singleton pregnancies the weighted pooled DR in 1,963 
cases of trisomy 21 was 99.7% (95% CI, 99.1-99.9%) and the FPR in 223,932 non-trisomy 21 
pregnancies was 0.04% (95% CI, 0.02-0.07%).1 In the combined total of 18 cases of trisomy 18 and 
3,143 non-trisomy 18 pregnancies the pooled weighted DR and FPR were 88.9% (95% CI 64.8, 
97.2%) and 0.03% (95% CI 0.00, 0.33%), respectively; in our meta-analysis of studies in singleton 
pregnancies the weighted pooled DR in 563 cases of trisomy 18 was 97.9% (95% CI, 94.9-99.1%) 
and the FPR in 222,013 non-trisomy 18 pregnancies was 0.04%, 95% CI 0.03-0.07%).1 The number of 
twin pregnancies with trisomy 13 (n=3) is too small for accurate assessment of DR. The average FPR 
for trisomy 13 of 0.19% (5/2,569) seems slightly higher than the values reported for singleton 
pregnancies (0.04%, 95% CI 0.02-0.07%).1 
 
In our study the method of cfDNA testing was targeted but in all other studies MPSS was used. 
Similarly, our study was confined to pregnancies in the first-trimester, whereas the other studies 
included pregnancies in the second and some in the third trimester. Although there was no obvious 
difference in performance of screening between our and that of the other studies the small number of 
cases prevented meaningful subgroup analyses, including chorionicity, cfDNA method for analysis, 
patient's background risk or gestational age at testing. 
 
This study has not addressed the issue of cfDNA test failure because we have recently reported our 
experience in a larger cohort including both singleton and twin pregnancies.25 In that study we found 
that important contributors to cfDNA test failure are increased maternal weight, conception by in vitro 
fertilization, Black or South Asian racial origin, dichorionicity, nulliparity, and low gestational age and 
low serum PAPP-A and free ß-hCG. Test failure after first sampling in dichorionic twins was 3.3 times 
higher than in singletons but to a great extent this excess failure rate can be attributed to the fact that 
a considerably higher proportion of twins were conceived by in vitro fertilization and more women 
were nulliparous. 
 
Comparison with results of previous meta-analyses in twin pregnancies 
 
Our previous meta-analysis on the performance of cfDNA testing for fetal aneuploidies in clinical 
validation or implementation studies included five studies in twin pregnancies; in a total of 24 cases of 
trisomy 21 and 1,111 unaffected cases the DR was 100% and FPR was 0%.1 Another meta-analysis 
examined four studies that included both singletons and twins and three studies that included only 
twins; it was not possible to extract the number of twin pregnancies that were evaluated but the 
authors reported that the DR of trisomy 21 in twins was 89.4% (95% 75-96%) and the FPR was 
0.4%.26  
 
Liao et al., conducted a meta-analysis of studies reporting on cfDNA testing in twin pregnancies.27 
They included 10 studies, one of which was retrospective, three were a mixture of retrospective and 
prospective and six were prospective; five were cohort studies, two were case-control studies and 
three had a mixture of cohort and case-control studies. The authors did not set any criteria on degree 
of follow up. In a combined total of 69 cases of trisomy 21 the DR was 99% (95% CI, 92-100%), in 13 
cases of trisomy 18 the DR was 85% (95% CI, 55-98%), in 3 cases of trisomy 13 the DR was 100% and 
in 2008 euploid pregnancies the FPR was 0.05%. Our meta-analysis included only prospective cohort 
studies with follow-up in at least 85% of cases to avoid reporting bias. Case-control studies were 
excluded because they tend to introduce an optimistic bias to the estimates of diagnostic 
performance. 
 
Implication for clinical practice 
 
This meta-analysis provides good evidence that the performance of cfDNA testing for trisomy 21 in 
twin pregnancies may be similar to that in singletons. In this respect, the performance of the cfDNA 
test is superior, both in terms of higher DR and substantially lower FPR, to that of the first trimester 
combined test or second trimester biochemical testing.28 This is particularly important in the case of 
dichorionic twins where both the incidence of aneuploidies and the invasive procedure-related risk of 
pregnancy loss are increased compared to singletons. If the pregnancies are discordant for an 
aneuploidy and the parents choose to have selective fetocide, the subsequent risk of miscarriage or 
early preterm birth increase with gestational age at fetocide;29 in this respect it would be preferable to 
offer screening leading to prenatal diagnosis in the first than the second trimester. 
 
A positive or high-risk cfDNA result should be confirmed by invasive testing. In the case of first-
trimester screening and positive cfDNA result for trisomy 21 the diagnostic test can be chorionic 
villous sampling. In the case of trisomies 18 and 13 a positive result should be followed by a detailed 
ultrasound examination and if the characteristic defects associated with these trisomies are detected 
then chorionic villous sampling can be carried out; if no defects are detected in the scan the preferred 
diagnostic test is amniocentesis to avoid an erroneous result due to placenta confined mosaicism. 
 
On the other hand, a negative or low-risk cfDNA result is reassuring that the fetus is unlikely to be 
affected by the trisomy under investigation. The posterior risk for a given patient can be obtained by 
multiplying the prior risk with the negative likelihood ratios calculated in this meta-analysis; the risk for 
trisomies 21 and 18 is reduced by a factor of 56 and 9, respectively. For example, if prior screening by 
the combined test had shown that the risk for trisomy 21 was 1 in 10 and cfDNA testing gives a low-
risk result the chance that the fetus is affected is 1 in 560; in contrast, if the risk for trisomy 18 from the 
combined test was 1 in 2 and cfDNA testing gives a low-risk result the chance that the fetus is affected 




Contrary to our previous meta-analysis in singleton pregnancies, the number of published studies 
analysing performance of cfDNA testing in twin pregnancies is very limited and consequently, the 
number of affected cases included in this meta-analysis is considerably smaller. However, the results 
reported in the literature for trisomies 21 and 18 present low heterogeneity and therefore they are 
likely to represent the real performance. There is an insufficient number of trisomy 13 cases to 
accurate assess performance.  
 
In the assessment of the quality of the included studies, all of them were considered to be at high-risk 
of selection bias and at high-risk of concerns regarding applicability in relation to patient selection 
because they were not performed as part of routine primary screening but they were carried out in 
preselected populations. However, the ability to detect aneuploidy with cfDNA analysis is dependent 
upon assay precision and fetal DNA percentage in the sample rather than the prevalence of the 
disease in the study population. Most studies were also classified as being at high-risk of bias in 
relation to flow and timing. This is essentially because cfDNA testing did not provide results in all 
cases, there was no complete follow up, or the method of determining outcome was not the same in 
all cases. However, such criticisms could be applied to any clinical study; all methods of traditional 
screening occasionally fail to give a result and no screening study in pregnancy can have complete 




Performance of cfDNA testing for trisomy 21 in twin pregnancies may be similar to that reported for 
singleton pregnancies. The number of cases of trisomies 18 and 13 is too small for accurate 
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Figure 1.  Flow chart for the systematic review. 
 
Figure 2. Summary of the quality of included studies using the Quality Assessment tool for Diagnostic 
Accuracy Studies (QUADAS-2) checklist.  
 
Figure 3. Forest plots of sensitivity and specificity with 95% confidence intervals (CI) and weighted 
pooled summary statistics using bivariate random-effects model in assessing cell-free DNA analysis in 
screening for trisomy 21.  
 
Figure 4. Forest plots of sensitivity and specificity with 95% confidence intervals (CI) and weighted 
pooled summary statistics using bivariate random-effects model in assessing cell-free DNA analysis in 
screening for trisomy 18.  
  
 
Table 1. Summary of characteristics of studies reporting on cell-free (cf) DNA analysis of maternal 

















GA (weeks) Population 
Lau (2013)17 T21 12 2 (16.7%) 1 
  
100 MPSS 13 (11-20) High-risk 
Huang (2014)18 T21, T18 189 33 (17.5%) 9 2 
 
100 MPSS 19 (11-36) High-risk 
Tan (2016)19 T21 510 3.2%* 4 
  
90 MPSS 12 (11-28) Mixture 
Du (2017)20 T21 92 39 (42.4%) 2 
  
100 MPSS 18 (14-23) High-risk 
Le Conte (2018)21 T21, T18, T13 418 86 (20.6%) 3 1 
 
85 MPSS 16 (10-35) Mixture 
Yang (2018)22 T21, T18 432 95 (22.0%) 4 1 
 
91 MPSS > 9 Mixture 
Yu (2019)23 T21, T18, T13 1157 308 (26.6%) 16 4 1 99 MPSS 18 (8-30) Mixture 
Current study T21, T18, T13 997 143 (14.3%) 17 10 2 94 Targeted 11 (10-14) Mixture 
  
* this is the value in the original sample before exclusions for failed results and no follow up. 
Only first author is given for each study. Numbers reported are those after exclusion of cases without 
a cfDNA test result or pregnancy outcome. Gestational age (GA) is given as median or mean (range). 
MPSS, massively parallel shotgun sequencing. 
 
  
Table 2. Studies reporting on the application of cell-free DNA analysis of maternal blood in screening 
for trisomy 21.  
 
 





Trisomy 21 Non trisomy 21 
Total 
Detection rate 
n (%, 95% CI) 
Total 
False positive rate 
n (%, 95% CI) 
Lau (2013)17 1 1 (100, 25.0 - 100) 11 0 (0, 0 - 28.49) 
Huang (2014)18 9 9 (100, 66.4 - 100) 180 0 (0, 0 - 2.03) 
Tan (2016)19 4 4 (100, 39.8 - 100) 506 0 (0, 0 - 0.73) 
Du (2017)20 2 2 (100, 15.8 - 100) 89 0 (0, 0 - 4.06 
Le Conte (2018)21 3 3 (100, 29.2 - 100) 414 1 (0.24, 0.01 - 1.34) 
Yang (2018)22 4 4 (100, 39.8 - 100) 396 0 (0, 0 - 0.93) 
Yu (2019)23 16 16 (100, 79.4 - 100) 1141 0 (0, 0 - 0.32) 
Current study 17 16 (94.1, 71.3 - 100) 980 1 (0.10, 0 - 0.57) 
Pooled analysis, %, (95% CI)* 98.2 (83.2 - 99.8) 0.05 (0.26 - 0.01) 
Heterogeneity assessment 0.020  0.011  
Likelihood ratio positive 1837 (369 - 9149) 
Likelihood ratio negative 0.018 (0.002 - 0.190) 
Table 3. Studies reporting on the application of cell-free DNA analysis of maternal blood in screening 
for trisomy 18.  
 
 




Trisomy 21 Non trisomy 21 
Total 
Detection rate 
n (%, 95% CI) 
Total 
False positive rate 
n (%, 95% CI) 
Huang (2014)18 2 1 (50.0, 1.3 - 98.7) 187 0 (0, 0 - 1.95) 
Le Conte (2018)21 1 1 (100, 2.5 - 100) 417 0 (0, 0 - 0.88) 
Yang (2018)22 1 1 (100, 2.5 - 100) 399 0 (0, 0 - 0.92) 
Yu (2019)23 4 4 (100, 39.8 - 100) 1153 0 (0, 0 – 0.32) 
Current study 10 9 (90, 55.5 - 99.8) 986 1 (0.10, (0 – 0.56) 
Pooled analysis, %, (95% CI)* 88.9 (64.8 - 97.2) 0.03% (0.33 - 0.00) 
Heterogeneity assessment 0 0 
Likelihood ratio positive 2774 (388 - 19823) 
Likelihood ratio negative 0.111 (0.30 - 0.411) 
